Get the Stockscreener App
27.04
1.40%
0.295
Summit Therapeutics Inc stock is traded at $27.04, with a volume of 884.00K.
It is up +1.40% in the last 24 hours and up +27.42% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$26.74
Open:
$26.98
24h Volume:
884.00K
Relative Volume:
0.20
Market Cap:
$20.10B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-84.48
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
-3.20%
1M Performance:
+27.42%
6M Performance:
+21.27%
1Y Performance:
+153.65%
1-Day Range:
$26.78
$27.69
1-Week Range:
$26.50
$29.07
52-Week Range:
$8.88
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
27.07 | 20.39B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.23 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.69 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
345.09 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
606.74 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.70 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser
Summit Therapeutics Inc. recovery potential after sell offConsistent Return Setup with Exit Strategy - Newser
Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser
Is Summit Therapeutics Inc. stock a growth or value playFree Day Trading Signals With High Precision - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser
Why is Summit Therapeutics Inc. stock attracting strong analyst attentionRapid-fire capital growth - jammulinksnews.com
Summit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Ivonescimab's Dual-Action Revolution: A Catalyst for Akeso and Summit Therapeutics in the $500M+ Lung Cancer Market - AInvest
Does Summit Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - jammulinksnews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Is Summit Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisVolume Spike Monitors - Newser
When is Summit Therapeutics Inc. stock expected to show significant growthAchieve consistent profits with proven strategies - jammulinksnews.com
Summit Therapeutics Jumps 4% As Technicals Signal Bullish Breakout Potential - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Summit Therapeutics Soars 4.64%—Could This Biotech Breakthrough Signal a Game-Changer? - AInvest
What drives Summit Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bank of New York Mellon Corp Has $6.57 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Will Summit Therapeutics Inc. stock benefit from AI tech trendsTriple-digit growth rates - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Summit Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
2.07%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):